Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) Antibodies:
anti-Mouse (Murine) Antibodies:
Go to our pre-filtered search.
Human Polyclonal NR2C2 Primary Antibody for IF (p), IHC (p) - ABIN701185
Wang, Zhao, Yu, Feng, Zhang, Kou, Chu, Cui, Li, Zhang, Shen, Min: Regulation of steroid hormones and energy status with cysteamine and its effect on spermatogenesis. in Toxicology and applied pharmacology 2016
Show all 3 Pubmed References
Human Polyclonal NR2C2 Primary Antibody for ELISA, WB - ABIN251479
Omori, Matsumoto, Sanjo, Sato, Akira, Smart, Ninomiya-Tsuji: TAK1 is a master regulator of epidermal homeostasis involving skin inflammation and apoptosis. in The Journal of biological chemistry 2006
Human Polyclonal NR2C2 Primary Antibody for IF (p), IHC (p) - ABIN746333
Dvashi, Goldberg, Adir, Shapira, Pollack: TGF-?1 induced transdifferentiation of rpe cells is mediated by TAK1. in PLoS ONE 2015
Human Polyclonal NR2C2 Primary Antibody for IF (p), IHC (p) - ABIN802023
Su, Zhou, Wang, Yang, Li, Yu, Li: The PPARβ/δ agonist GW501516 attenuates peritonitis in peritoneal fibrosis via inhibition of TAK1-NFκB pathway in rats. in Inflammation 2014
Human Polyclonal NR2C2 Primary Antibody for WB - ABIN4357771
Liepelt, Mossanen, Denecke, Heymann, De Santis, Tacke, Marx, Ostareck, Ostareck-Lederer: Translation control of TAK1 mRNA by hnRNP K modulates LPS-induced macrophage activation. in RNA (New York, N.Y.) 2014
inhibition of TAK1 triggered two caspase 8 (show CASP8 Antibodies) activation pathways through the induction of RIP1 (show RALBP1 Antibodies)-FADD (show FADD Antibodies)-caspase 8 (show CASP8 Antibodies) complex as well as FLIP cleavage/degradation.
Transforming growth factor-beta activated kinase 1 (TAK1 (show MAP3K7 Antibodies)) regulation of sterol-regulatory element-binding proteins (SREBPs) critically contributes to the maintenance of liver homeostasis to prevent steatosis, which is a potentially important mechanism to prevent hepatocellular carcinoma (HCC (show FAM126A Antibodies)) development.
TAK1 regulates Nrf2 (show NFE2L2 Antibodies) through modulation of Keap-p62/SQSTM1 (show SQSTM1 Antibodies) interaction. This regulation is important for homeostatic antioxidant protection in the intestinal epithelium.
CNS-specific Tak1 deletion prevented ER-stress-induced hypothalamic leptin (show LEP Antibodies) resistance and hyperphagic obesity under a high-fat diet (HFD). Thus, TAK1 is a crucial regulator of ER stress in vivo, which could be a target for alleviation of ER stress and its associated disease conditions.
SIRT7 inhibits TR4 degradation by deacetylation of DDB1.
this study shows that TAK1 negatively regulates lipopolysaccharide-induced cytokine secretion in myeloid cells by inhibiting MEKK3 (show MAP3K3 Antibodies) activities
TR4 binds GR to play an important role in glucocorticoid-directed corticotroph tumor POMC (show POMC Antibodies) regulation in addition to modulating glucocorticoid actions on other GR targets.
Mekk1 (show MAP2K1 Antibodies) (encoded by Map3k1 (show MAP3K1 Antibodies)) signaling activates Mapks to regulate Cdkn1b (show CDKN1B Antibodies) (encoding p27(Kip1 (show CDKN1B Antibodies))) expression and p27(Kip1 (show CDKN1B Antibodies))-dependent proliferative expansion in response to antigen.
TRADD (show TRADD Antibodies) knockout blunts pressure overload-induced cardiac hypertrophy through mediating TAK1/p38 MAPK (show MAPK14 Antibodies) but not AKT (show AKT1 Antibodies) phosphorylation
The present study demonstrates that TIPE2 (show TNFAIP8L2 Antibodies) acts as a novel negative regulator of inflammatory and immune responses through TAK1 signaling.
High TAK1 (show MAP3K7 Antibodies) expression is associated with the progression of hepatocellular carcinoma.
Here, we report that Pseudomonas aeruginosa ExoY inhibits proinflammatory cytokine production through suppressing the activation of TAK1 (show MAP3K7 Antibodies) as well as downstream NF-kappaB (show NFKB1 Antibodies) and mitogen-activated protein (MAP) kinases.
this study shows that TAP1 (show TAP1 Antibodies) plays a novel role in the negative regulation of virus-triggered NF-kappaB (show NFKB1 Antibodies) signaling and the innate immune response by targeting the TAK1 (show MAP3K7 Antibodies) complex
TAK1 (show MAP3K7 Antibodies)/TAB1 (show TAB1 Antibodies) expression in non-small cell lung carcinoma tissue is significantly increased and closely associated with patient clinical prognosis.
miR (show MLXIP Antibodies)-203 represses NF-kappaB (show NFKB1 Antibodies) signaling via targeting TAK1 (show MAP3K7 Antibodies) and PI3KCA and miR (show MLXIP Antibodies)-203 overexpression may contribute to the COPD (show ARCN1 Antibodies) initiation.
DK1 (show DOLK Antibodies) inhibits the formation of the TAK1 (show MAP3K7 Antibodies)-TAB2 (show TAB2 Antibodies)-TRAF6 (show TRAF6 Antibodies) complex and leads to the inhibition of TRAF6 (show TRAF6 Antibodies) ubiquitination.
IFIT5 promotes SeV-induced IKK (show CHUK Antibodies) phosphorylation and NF-kappaB (show NFKB1 Antibodies) activation by regulating the recruitment of IKK (show CHUK Antibodies) to TAK1 (show MAP3K7 Antibodies).
USP18 (show USP18 Antibodies) negatively regulates NF-kappaB (show NFKB1 Antibodies) signaling by targeting TAK1 (show MAP3K7 Antibodies) and NEMO (show IKBKG Antibodies) for deubiquitination through distinct mechanisms.
Members of the nuclear hormone receptor family, such as NR2C2, act as ligand-activated transcription factors. The proteins have an N-terminal transactivation domain, a central DNA-binding domain with 2 zinc fingers, and a ligand-binding domain at the C terminus. The activated receptor/ligand complex is translocated to the nucleus where it binds to hormone response elements of target genes (Yoshikawa et al., 1996
TGF-beta activated kinase 1
, mitogen-activated protein kinase kinase kinase 7
, TGF-beta-activated kinase 1
, mitogen activated protein kinase kinase kinase 7
, transforming growth factor beta-activated kinase 1
, transforming growth factor-beta-activated kinase 1
, Nuclear hormone receptor TR4
, TR4 nuclear hormone receptor
, nuclear receptor subfamily 2 group C member 2
, orphan nuclear receptor TAK1
, orphan nuclear receptor TR4
, testicular nuclear receptor 4
, testicular receptor 4
, nuclear receptor subfamily 2, group H, member 2
, orphan receptor, TR4
, TR4 orphan receptor
, TR4-NS orphan receptor
, orphan receptor TR4